2023 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial | Llovet, Josep M; Kudo, Masatoshi; Merle, Philippe; Meyer, Tim; Qin, Shukui; Ikeda, Masafumi; Xu, Ruocai; Edeline, Julien; Ryoo, Baek-Yeol; Ren, Zhenggang; Masi, Gianluca; Kwiatkowski, Mariusz; Lim, Ho Yeong; Kim, Jee Hyun; Breder, Valeriy; Kumada, Hiromitsu; ANN-LII CHENG ; Galle, Peter R; Kaneko, Shuichi; Wang, Anran; Mody, Kalgi; Dutcus, Corina; Dubrovsky, Leonid; Siegel, Abby B; Finn, Richard S | The Lancet. Oncology | 24 | | |